Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Liver Transplant Rejection Pipeline Review, H2 2016 Edition - Research and Markets

Research and Markets
Posted on: 27 Oct 16

Research and Markets has announced the addition of the "Liver Transplant Rejection - Pipeline Review, H2 2016" report to their offering.

'Liver Transplant Rejection - Pipeline Review, H2 2016'; Liver Transplant Rejection pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities

Institutes.

'Liver Transplant Rejection - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects. Currently, The molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Liver Transplant Rejection Overview
  3. Therapeutics Development
  4. Pipeline Products for Liver Transplant Rejection - Overview
  5. Pipeline Products for Liver Transplant Rejection - Comparative Analysis
  6. Liver Transplant Rejection - Therapeutics under Development by Companies
  7. Liver Transplant Rejection - Therapeutics under Investigation by Universities/Institutes
  8. Liver Transplant Rejection Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Liver Transplant Rejection - Products under Development by Companies
  13. Liver Transplant Rejection - Products under Investigation by Universities/Institutes
  14. Liver Transplant Rejection - Companies Involved in Therapeutics Development
  • Astellas Pharma Inc.
  • Biogen Inc
  • Conatus Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • Novartis AG
  • RedHill Biopharma Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/c7v6r3/liver_transplant

View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006220/en/

Business Wire
www.businesswire.com

Last updated on: 27/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.